Results 151 to 160 of about 22,884 (253)

Delivering Proteins and Enzymes to Solid Tumors Through the Development of Stimuli‐Responsive Nanocarriers

ChemNanoMat, Volume 12, Issue 6, June 2026.
Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo, Diana Benita‐Donadios, Sandra Jiménez‐Falcao, Alejandro Baeza   +3 more
wiley   +1 more source

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes. [PDF]

Front Med Technol
Haon B, Hartmann M, Akodad S, Stevens H, Rochaix L.   +4 more
europepmc   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Increasing access to CAR-T therapy: a case study of an academic hospital's alternative innovation model. [PDF]

Orphanet J Rare Dis
Ruiz AA, Shinabargar E, Slovenski I, Large K, Vieira M, Moon S.   +5 more
europepmc   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

Assessing rare disease understanding: a novel disease readiness level framework. [PDF]

Orphanet J Rare Dis
Kitahara K, Kano S.
europepmc   +1 more source

Spatial and Phenotypic Heterogeneity of ILC Subsets in Mouse Lung Under Type 2 Inflammatory Conditions

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Using cyclic multiplex microscopy in an IL‐33‐driven type 2 inflammation model, we validated a spatial workflow mapping rare lung ILCs. High‐dimensional analysis revealed a conserved peri‐lymphatic niche at early time points of inflammation where ILC2s and myeloid cells co‐localize with LYVE1+ vessels, highlighting a structured immunological ...
Sandy Kroh, Anna Pascual‐Reguant, Artür Manukyan, Ralf Uecker, Robert Günther, Lars Philipsen, Ralf Koehler, Peggy Mex, Markus Landthaler, Raluca A. Niesner, Anja E. Hauser   +10 more
wiley   +1 more source

Orphan Drug Approval in Canada, 1999-2022: A Cross-sectional Study. [PDF]

Int J Health Policy Manag
Lexchin J.
europepmc   +1 more source

Clinical outcomes of mitochondrial‐enhancing nutraceutical supplementation in psychiatric disorders: A systematic review

General Psychiatry, Volume 39, Issue 3, June 2026.
ABSTRACT Background Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders.
Juan Tortajada, Bengisu Kevser Bulduk, Belén Alfonso‐Landete, Paula Alcaide‐Barriga, Bernat Ballvé‐Gelonch, Glòria Garrabou, Elisabet Vilella, Yolanda Alonso, Alba Valiente‐Pallejà, Lourdes Martorell   +9 more
wiley   +1 more source